DiaMedica Therapeutics Inc. announced the first patient being dosed in DiaMedica's relaunch of its pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the treatment of acute ischemic stroke. The company continues to work closely with its contract research organization (CRO), on re-engaging with study sites for the ReMEDy2 Trial. The trial is intended to enroll approximately 350 patients at up to 100 sites globally.

The majority of the U.S. sites are expected to be activated by the end of the third quarter of 2024. DiaMedica is the first company to have developed and clinically studied rKLK1. Non-recombinant, tissue extracted KLK1, produced from the pancreas ofigs and human urine, has been approved for decades for patients in Japan, China and South Korea with a variety of ischemic conditions such as AIS, chronic renal disease, retinopathy and hypertension.

DM199/rKLK1 is currently being studied in patients with AIS. In September 2021, the FDA granted Fast Track Designation to DM199 for the treatment of AIS.